Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry

Blood (2021) 137 (20): 2838–2847.

https://doi.org/10.1182/blood.2020010529

Published: 2021

Includes: Supplemental data

Journal Articles

Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease

Stephanie Williams, MD, Rama Nanah, MD, Darci Zblewski, CNP, Michelle Elliott, MD, William J. Hogan, MBChB, Raoul Tibes, MD PhD, James M. Foran, MD, Mark R. Litzow, MD, Aref Al-Kali, MD

Blood (2016) 128 (22): 2799.

https://doi.org/10.1182/blood.V128.22.2799.2799

Published: 2016

Journal Articles

Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates

Ryan D. Gentzler, MD, MS, Andrew M. Evens, DO, MSc, Alfred W. Rademaker, PhD, Bharat B Mittal, M.D., Adam M. Petrich, MD, Jessica K. Altman, MD, Olga Frankfurt, MD, Daina Variakojis, MD, Seema Singhal, M.D., Jayesh Mehta, MD, Joel R Green, MD, Stephanie Williams, MD, Lynne Kaminer, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2012) 120 (21): 2024.

https://doi.org/10.1182/blood.V120.21.2024.2024

Published: 2012

Journal Articles

Tacrolimus Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients Receiving Concomitant Voriconazole.

Steven Trifilio, Judy Pi, Seema Singhal, Olga Frankfurt, Andrew Evens, Leo Gordon, Martin Tallman, Jane Winter, Stephanie Williams, Jayesh Mehta

Blood (2007) 110 (11): 4956.

https://doi.org/10.1182/blood.V110.11.4956.4956

Published: 2007

Journal Articles

Outcome of Relapse after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) - The Effect of the Underlying Disease on Survival Following Relapse.

Seema Singhal, Olga Frankfurt, Andrew Evens, Leo Gordon, Martin Tallman, Stephanie Williams, Jane Winter, David Grinblatt, Lynne Kaminer, Jayesh Mehta

Blood (2007) 110 (11): 5020.

https://doi.org/10.1182/blood.V110.11.5020.5020

Published: 2007

Journal Articles

Submyeloablative Allografts for Hematologic Malignancies: Validation of a Prognostic Model Based on Pre-Transplant Variables.

Jayesh Mehta, Jane Winter, Martin Tallman, Leo Gordon, Stephanie Williams, Olga Frankfurt, Andrew Evens, David Grinblatt, Lynne Kaminer, Richard Meagher, Seema Singhal

Blood (2006) 108 (11): 3036.

https://doi.org/10.1182/blood.V108.11.3036.3036

Published: 2006

Journal Articles

Reduced-Intesity Allogeneic HSCT in Hematologic Malignancies: Influence of Underlying Diagnosis and Prior Autograft on Outcome.

Jayesh Mehta, Leo Gordon, Martin Tallman, Jane Winter, Stephanie Williams, Olga Frankfurt, Andrew Evens, David Grinblatt, Lynne Kaminer, Richard Meagher, Kamran Rashid, Donna Grabowski, Seema Singhal

Blood (2006) 108 (11): 3040.

https://doi.org/10.1182/blood.V108.11.3040.3040

Published: 2006

Journal Articles

Breakthrough Fungal Infections after Allogeneic Hematopoietic Stem Cell Transplantation in Patients on Prophylactic Voriconazole.

Steve Trifilio, Seema Singhal, Stephanie Williams, Jane Winter, Martin Tallman, Leo Gordon, Olga Frankfurt, Andrew Evens, Jayesh Mehta

Blood (2006) 108 (11): 2849.

https://doi.org/10.1182/blood.V108.11.2849.2849

Published: 2006

Journal Articles

90 Y Ibritumomab Tiuxetan (Zevalin®; 90 YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.

Jane N. Winter, MD, David Inwards, M.D., Stewart Spies, M.D., Gregory Wiseman, M.D., David Patton, B.S., William Erwin, M.S., Alfred Rademaker, Ph.D., Stephanie Williams, M.D., Martin S. Tallman, M.D., Ivana Micallef, M.D., Jayesh Mehta, M.D., Seema Singhal, M.D., Andrew Evens, D.O., Michael Zimmer, Ph.D., Arturo Molina, M.D., Christine White, M.D., Leo I. Gordon, M.D.

Blood (2006) 108 (11): 330.

https://doi.org/10.1182/blood.V108.11.330.330

Published: 2006

Journal Articles

Submyeloablative Allogeneic HSCT for Hematologic Malignancies: Effect of Body Weight.

Seema Singhal, Leo Gordon, Martin Tallman, Jane Winter, Stephanie Williams, Olga Frankfurt, Andrew Evens, Richard Meagher, Lynne Kaminer, David Grinblatt, Jayesh Mehta

Blood (2006) 108 (11): 2949.

https://doi.org/10.1182/blood.V108.11.2949.2949

Published: 2006

Journal Articles

Durable Event-Free and Overall Survival (EFS/OS) in Mantle Cell Lymphoma (MCL) without Rituximab: Long-Term Follow-Up of a Phase II Trial with Intensive Chemotherapy (CTAP/VMAC) Followed by Autologous Hematopoietic Stem Cell Transplant (aHSCT).

Andrew M. Evens, DO, MS, Jane N. Winter, MD, Nanjiang Hou, MS, Fred Rademaker, PhD, Katalin Kelemen, MD, Beverly Nelson, MD, David Patton, BS, Olga Frankfurt, MD, Stephanie Williams, MD, Seema Singhal, MD, Martin S. Tallman, MD, Steven T. Rosen, MD, Jayesh Mehta, MD, Leo I. Gordon, MD

Blood (2006) 108 (11): 2448.

https://doi.org/10.1182/blood.V108.11.2448.2448

Published: 2006

Journal Articles

Autologous Stem Cell Transplantation (AuSCT) with Total Lymphoid Irradiation (TLI) and High-Dose Chemotherapy (CT) Results in High Survival Rates for “Poor-Prognosis” Relapsed/Refractory (R/R) Hodgkin’s Disease (HD): Multivariate Analysis of Outcome Shows Marked Benefit for TLI in a Prospective Phase I/II Trial.

Andrew M. Evens, DO, MS, Alfred Rademaker, PhD, Bharat B. Mittal, MD, Jessica K. Altman, MD, David Patton, BS, Lynne Kaminer, MD, Seema Singhal, MD, Daina Variakojis, MD, Stephanie Williams, MD, Martin S. Tallman, MD, Jayesh N. Mehta, MD, Jane N. Winter, MD, Leo I. Gordon, MD

Blood (2005) 106 (11): 2080.

https://doi.org/10.1182/blood.V106.11.2080.2080

Published: 2005

Journal Articles

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Azra Raza, MD, Natalie Callander, MD, Leonel Ochoa, MD, Lawrence Piro, MD, Peter Emanuel, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Howard Burris, III, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Curtain, MD, Richard Larson, MD, Shelby Young, RN, Gail L. Brown, MD

Blood (2005) 106 (11): 2520.

https://doi.org/10.1182/blood.V106.11.2520.2520

Published: 2005

Journal Articles

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Natalie Callander, MD, Jose L. Ochoa-Bayona, MD, Lawrence Piro, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Ira Oliff, MD, Howard Burris, III, MD, Anneliese Jameson, Kiran Patel, Gail L. Brown, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Emanuel, MD

Blood (2004) 104 (11): 1428.

https://doi.org/10.1182/blood.V104.11.1428.1428

Published: 2004

NARROW

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry

Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease

Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates

Tacrolimus Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients Receiving Concomitant Voriconazole.

Outcome of Relapse after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) - The Effect of the Underlying Disease on Survival Following Relapse.

Submyeloablative Allografts for Hematologic Malignancies: Validation of a Prognostic Model Based on Pre-Transplant Variables.

Reduced-Intesity Allogeneic HSCT in Hematologic Malignancies: Influence of Underlying Diagnosis and Prior Autograft on Outcome.

Breakthrough Fungal Infections after Allogeneic Hematopoietic Stem Cell Transplantation in Patients on Prophylactic Voriconazole.

90 Y Ibritumomab Tiuxetan (Zevalin®; 90 YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.

Submyeloablative Allogeneic HSCT for Hematologic Malignancies: Effect of Body Weight.

Durable Event-Free and Overall Survival (EFS/OS) in Mantle Cell Lymphoma (MCL) without Rituximab: Long-Term Follow-Up of a Phase II Trial with Intensive Chemotherapy (CTAP/VMAC) Followed by Autologous Hematopoietic Stem Cell Transplant (aHSCT).

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only